Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05144529 · ClinicalTrials.gov registry record · Phase 2

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

A Phase 2 study of Lung Cancer Metastatic, sponsored by Scott Antonia.

Active
Registry status
Phase 2
Development phase
38
Enrollment target
1
Study location

NCT05144529 is a Phase 2 study of Lung Cancer Metastatic that is active but no longer recruiting, run by Scott Antonia. The registered enrollment target is 38 participants, below the 364-participant average among 8 other Lung Cancer Metastatic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05144529, a Phase 2 study of Lung Cancer Metastatic, is active but no longer recruiting, sponsored by Scott Antonia.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer). Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs which are approved for the treatment of advanced lung cancer that has expression of PD-L1 greater than or equal to 1%. Evolucumab is being combined with nivolumab and ipilimumab to see if it will improve the anti-tumor capabilities of the immunotherapy. Adding evolocumab to the combination of nivolumab and ipilimumab has not been tested in people before and is considered investigational.

Conditions Studied

Lung Cancer Metastatic

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG Evolocumab

Study Locations (1)

North Carolina

  • Duke Univ. Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2022-03-22
Est. Completion 2027-06
Phase Phase 2

Sponsor

Scott Antonia

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05144529

The ClinicalTrials.gov registry entry for NCT05144529 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 364-participant average among 8 other Lung Cancer Metastatic trials with a reported enrollment target (90% lower). The listed sponsor is Scott Antonia, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer Metastatic appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT05144529 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05144529 about?

NCT05144529 is a clinical study titled "A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC". This is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer). Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs which are approved ...

What is the current status of trial NCT05144529?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2022-03-22. Estimated completion is 2027-06.

What conditions does trial NCT05144529 study?

This clinical trial studies the following conditions: Lung Cancer Metastatic.

What interventions are being tested in trial NCT05144529?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Evolocumab (DRUG).

Who is sponsoring clinical trial NCT05144529?

This trial is sponsored by Scott Antonia, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05144529 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer Metastatic

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.